Nuvation Bio IncNYSE:NUVB
- LAST PRICE2.9300
- TODAY'S CHANGE (%)-0.0500 (-1.6779%)
- Bid / Lots2.9300/ 9
- Ask / Lots2.9800/ 1
- Open / Previous Close3.0100 / 2.9800
- Day Range
- 52 Week Range
- Volume820,836
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NUVB |
|---|---|---|
| 09:32 ET | 17035 | 3.025 |
| 09:34 ET | 1890 | 3.015 |
| 09:36 ET | 562 | 3.0195 |
| 09:38 ET | 4900 | 2.99 |
| 09:39 ET | 1078 | 2.995 |
| 09:41 ET | 1560 | 3.0076 |
| 09:43 ET | 200 | 2.995 |
| 09:45 ET | 8575 | 2.97 |
| 09:48 ET | 4535 | 2.96 |
| 09:50 ET | 946 | 2.96 |
| 09:52 ET | 2400 | 2.97 |
| 09:54 ET | 15361 | 2.9682 |
| 09:56 ET | 12493 | 2.975 |
| 09:57 ET | 316 | 2.975 |
| 09:59 ET | 289 | 2.975 |
| 10:01 ET | 2131 | 2.98 |
| 10:03 ET | 4651 | 2.975 |
| 10:06 ET | 4717 | 2.995 |
| 10:08 ET | 2475 | 3 |
| 10:10 ET | 14591 | 2.98 |
| 10:12 ET | 4296 | 2.995 |
| 10:14 ET | 36413 | 3 |
| 10:15 ET | 14379 | 2.995 |
| 10:17 ET | 46118 | 3.025 |
| 10:19 ET | 31918 | 3.009 |
| 10:21 ET | 1371 | 3.005 |
| 10:24 ET | 4722 | 3 |
| 10:26 ET | 754 | 3.005 |
| 10:28 ET | 6034 | 2.995 |
| 10:30 ET | 4119 | 3.005 |
| 10:32 ET | 6830 | 2.995 |
| 10:33 ET | 4342 | 2.995 |
| 10:35 ET | 1372 | 2.995 |
| 10:37 ET | 1400 | 3 |
| 10:39 ET | 12559 | 2.985 |
| 10:42 ET | 500 | 2.985 |
| 10:44 ET | 840 | 2.98 |
| 10:46 ET | 7245 | 2.97 |
| 10:48 ET | 1000 | 2.975 |
| 10:50 ET | 450 | 2.975 |
| 10:51 ET | 100 | 2.97 |
| 10:53 ET | 700 | 2.975 |
| 10:55 ET | 400 | 2.975 |
| 10:57 ET | 417 | 2.975 |
| 11:00 ET | 721 | 2.975 |
| 11:02 ET | 2139 | 2.98 |
| 11:04 ET | 600 | 2.98 |
| 11:06 ET | 200 | 2.9766 |
| 11:08 ET | 650 | 2.975 |
| 11:09 ET | 300 | 2.975 |
| 11:11 ET | 300 | 2.9725 |
| 11:13 ET | 1200 | 2.975 |
| 11:15 ET | 1500 | 2.975 |
| 11:18 ET | 400 | 2.9725 |
| 11:20 ET | 700 | 2.98 |
| 11:22 ET | 300 | 2.98 |
| 11:24 ET | 200 | 2.98 |
| 11:26 ET | 1567 | 2.975 |
| 11:27 ET | 2312 | 2.98 |
| 11:29 ET | 2439 | 2.9791 |
| 11:31 ET | 1200 | 2.9791 |
| 11:33 ET | 6920 | 2.99 |
| 11:36 ET | 600 | 2.99 |
| 11:38 ET | 1200 | 2.985 |
| 11:40 ET | 700 | 2.99 |
| 11:42 ET | 500 | 2.99 |
| 11:44 ET | 49921 | 2.945 |
| 11:45 ET | 7829 | 2.945 |
| 11:47 ET | 3180 | 2.945 |
| 11:49 ET | 400 | 2.95 |
| 11:51 ET | 3477 | 2.95 |
| 11:54 ET | 26621 | 2.95 |
| 11:56 ET | 1450 | 2.945 |
| 11:58 ET | 25164 | 2.925 |
| 12:00 ET | 500 | 2.925 |
| 12:02 ET | 1300 | 2.925 |
| 12:03 ET | 12233 | 2.92 |
| 12:05 ET | 779 | 2.925 |
| 12:07 ET | 1913 | 2.93 |
| 12:09 ET | 10881 | 2.935 |
| 12:12 ET | 880 | 2.935 |
| 12:14 ET | 400 | 2.935 |
| 12:16 ET | 787 | 2.935 |
| 12:18 ET | 11993 | 2.925 |
| 12:20 ET | 12485 | 2.935 |
| 12:21 ET | 300 | 2.94 |
| 12:25 ET | 200 | 2.94 |
| 12:27 ET | 200 | 2.94 |
| 12:30 ET | 950 | 2.93 |
| 12:32 ET | 8156 | 2.9457 |
| 12:34 ET | 5965 | 2.945 |
| 12:36 ET | 2378 | 2.95 |
| 12:38 ET | 2800 | 2.95 |
| 12:39 ET | 1900 | 2.945 |
| 12:41 ET | 10925 | 2.935 |
| 12:43 ET | 500 | 2.9387 |
| 12:45 ET | 3315 | 2.935 |
| 12:48 ET | 33802 | 2.91 |
| 12:50 ET | 4514 | 2.915 |
| 12:52 ET | 1300 | 2.91 |
| 12:54 ET | 2232 | 2.915 |
| 12:56 ET | 2306 | 2.92 |
| 12:57 ET | 35335 | 2.92 |
| 12:59 ET | 41360 | 2.93 |
Jun 3, 2024
DJ Nuvation Bio Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:46AM ET on Monday Jun 03, 2024 by Dow Jones
6:46AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nuvation Bio Inc | 736.6M | -9.3x | --- |
CARGO Therapeutics Inc | 725.8M | -5.3x | --- |
89Bio Inc | 747.7M | -3.7x | --- |
Hillevax Inc | 710.0M | -4.3x | --- |
Savara Inc | 707.0M | -11.3x | --- |
Perspective Therapeutics Inc | 706.8M | -6.6x | --- |
Company Information
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Contact Information
- Headquarters
- 357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103
- Phone
- 415-754-3517
- Fax
- 302-636-5454
Executives
- Independent Chair of the Board
- Daniel Welch
- President, Chief Executive Officer, Founder, Director
- David Hung
- Principal Financial and Accounting Officer, Vice President - Finance
- Moses Makunje
- Chief Executive Officer of AnHeart Therapeutics and Director
- Junyuan Wang
- Chief People Officer
- Stacy Markel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $736.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
